Search

Search Results

• School health program in Debrecen: health from the beginning

  65-74

  Csaba Papp

  Views:

  151

  With the support of the Debrecen County Municipality at Pósa Street No. 1., a nationwide unique school health program has been launched at the Health Development Institute, which establishment was inaugurated on the 11th of October 2019 as part of the Clinical Center of the University of Debrecen. As it is well known, within the framework of the school health care program, operating on the basis of NM decrees 26/1997. (IX. 3.), 51/1997. (XII. 18.) and 33/1998. (VI. 24.), primary and secondary school students participate in mandatory screening tests every two years - during the so-called "indicator" years (the 2nd, 4th, 6th, 8th, 10th and 12th). The goal of DAEFI is to centralise school health objectives and additional examinations as part of a particular model program. After the coronavirus epidemic, the 2021/2022 academic year was the first full term when the screenings defined by the legislation could take place with the coordination of DAEFI, which preventive measures, with parental consent, were supplemented with an EKG examination as well as Prevention Lectures. We are now presenting the experiences of this first year.

• Assessment of the tasks performed by Nursing and Patient Care - Physiotherapy students and the experiences related to their professional studies in the defence against COVID-19

  32-46

  Blanka Besenyei

  Attila Csaba Nagy

  Ilona Balajti

  Views:

  67

  The epidemiological situation caused by COVID-19 has led to a need for help in the health care system for students of health sciences. The aim of our research is to assess the experiences of physiotherapy students in Debrecen during the protection against COVID-19. Using a questionnaire method, we wanted to collect information on the extent to which the students were able to use what they had learned and how the practical experience they had gained contributed to their professional development.

• The relationship between coronavirus and the renin-angiotensin system in the light of the development of drugs to treat COVID-19

  58-67

  Rudolf Gesztelyi

  Views:

  84

  SARS-Co-V of the Coronaviridae family emerged in 2019 in China and soon generated a pandemic.
  Albeit COVID-19 did not have as high death toll as some earlier pandemics, the severity and course of
  disease proved to be unpredictable if factors related to general health and case history of patients were
  considered. Thus COVID-19 due to its potentially fatal outcome and unpredictability demanded protective measures to be taken that were not sustainable in the long run (e.g. quarantining masses of people) during the early course of the pandemic (prior to the availability of vaccination and medications).
  Nonetheless, the vaccine for COVID-19, albeit showed efficacy, failed to reach the level of protection the
  former vaccines for other communicable diseases did. Additionally, available pharmaceutical treatmentregimens were not efficacious enough in preventing fatal outcome or long-term complications. These
  facts underscore the necessity of initiatives that seek future avenues for drug development, with special emphasis being placed on repositioning of medications with well-established use. Upon reviewing
  available scientific evidence four potential approaches may be identified that if repositioned could be
  evaluated as anti-COVID-19 agents: 1.) manipulating the a renin-angiotensin system by the use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); 2.) inhibiting the
  binding between human ACE2 enzyme and SARS-CoV-2 spike protein by N-acetylcysteine, or possibly
  quercetin; 3.) increasing the activity of ACE2 using ibuprofen; 4.) administration of prebiotics, probiotics
  or tryptophan to normalize SARS-CoV-2 induced dysbiotic changes of the microbiome.